Clinical trial · Interventional
Effects of Myo-inositol in Women With Polycystic Ovary Syndrome
Effects of Myo-inositol on the Menstrual Cycle, Hyperandrogenism, Chronic Inflammatory Process and Carbohydrate Metabolism in Women With Polycystic Ovary Syndrome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study will be carried out at the hospital of the medical school of sao paulo (HC-FMUSP) and the goal is to compare the effects of the administration of myo-inositol in relation to the effects of metformin in women with Polycystic Ovary Syndrome and insulin resistance or glucose intolerance. Menstrual cycle, hyperandrogenism, chronic inflammatory process, carbohydrate metabolism, hepatic steatosis will be evaluated. In total, 60 women in the reproductive period, with a variable age between 18 and 36 years old will be recruited and randomized in two groups: intervention- myo-inositol for 6 months, control group will use metformin also for 6 months.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glucose Intolerance | — | UNRESOLVED | — |
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
| Resistance, Insulin | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metformin | Drug | Metformin | ALIAS |
| Myo-inositol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Myo-inositol
- description
- 30 women with resistance insulin or glucose intolerance will receive myo-inositol 2g + folic acid 200mcg, orally, twice a day for 6 months.
- interventionNames
- Drug: Myo-inositol
- type
- ACTIVE_COMPARATOR
- label
- Metformin
- description
- 30 women with resistance insulin or glucose intolerance will receive metformin 850 mg, orally, twice a day for 6 months
- interventionNames
- Drug: Metformin
Primary outcomes (8)
- measure
- Menstrual cycle
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 19 Years
- Maximum age
- 36 Years
Show eligibility criteria text
Inclusion Criteria: * Women aged 19 to 36 with diagnosis of PCOS and insulin resistance or glucose intolerance. Exclusion Criteria: * Previous use of any hormonal treatment in the past three months; * Other causes of anovulation; * Gynecological or other associated conditions (endometriosis, adenomyosis or diabetes mellitus); * FSH (Follicle Stimulating Hormone) \> 15 Ul / L (2nd to 5th day of the cycle); * Beta-hcG (human chorionic gonadotropin) positive (pregnancy).
References
Publications (0)
Data not yet available